Possible involvement of Syndecan-1 in the state of COVID-19 related to endothelial injury
Tóm tắt
The coronavirus infection 2019 (COVID-19) is associated with microvascular endothelial injury. Here, we report that syndecan-1, a component of endothelial glycocalyx, may reflect the disease state of COVID-19 related to endothelial injury. A patient with COVID-19 was transferred to the intensive care unit of our hospital. Computed tomography of the chest showed bilateral ground glass opacities, which was diagnosed as acute respiratory syndrome. The PaO2/FIO2 ratio gradually increased from 158 on hospitalization to 300 on Day 11, on which day the ventilator was withdrawn. However, serum syndecan-1 (SDC-1) level gradually decreased from 400.5 ng/ml at hospitalization to 165.1 ng/ml on Day 5. On Day 6, serum SDC-1 level increased to 612.9 ng/ml owing to a systemic thrombosis with an increase in D-dimer. Serum SDC-1 level then decreased until 206.0 ng/ml on Day 11 after a decrease in D-dimer. The patient was transferred to another hospital on Day 21 after hospitalization. In this case report, changes in serum SDC-1 level closely reflected the change in disease condition in a patient with COVID-19. Serum SDC-1 may be a useful biomarker for monitoring the disease state of critically ill patients with COVID-19.
Tài liệu tham khảo
Matthay MA. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18.
Okada H, Yoshida S, Hara A, Ogura S, Tomita H. Vascular endothelial injury exacerbates coronavirus disease 2019: The role of endothelial glycocalyx protection. Crit Care Explor. 2020;2(10):e0272. https://doi.org/10.1097/CCE.0000000000000272.
Chang JC. Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease. 2019;17:10.
Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Trans Res. 2020;220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007.
Fraser DD, Patterson EK, Slessarev M, Gill SE, Martin C, Daley M, Miller MR, Patel MA, Dos Santos CC, Bosma KJ, O’Gorman DB, Cepinskas G. Endothelial injury and Glycocalyx degradation in critically ill coronavirus disease 2019 patients: implications for microvascular platelet aggregation. Crit Care Explor. 2020;2(9):e0194. https://doi.org/10.1097/CCE.0000000000000194.
Stahl K, Gronski PA, Kiyan Y, Seeliger B, Bertram A, Pape T, Welte T, Hoeper MM, Haller H, David S. Injury to the endothelial Glycocalyx in critically ill COVID-19 patients. Am J Respir Crit Care Med. 2020; in press.
Rehm M, Bruegger D, Christ F, Conzen P, Thiel M, Jacob M, Chappell D, Stoeckelhubar M, Welsch U, Reichart B, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007;116:1896–906.
Arthur A, McCall PJ, Jolly L, Kinsella J, Kirk A, Shelley BG. Endothelial glycocalyx layer shedding following lung resection. Biomark Med. 2016;10:1033–8.
Murphy LS, Wickersham N, McNeil JB, Shaver CM, May AK, Bastarache JA, Ware LB. Endothelial glycocalyx degradation is more severe in patients with non-pulmonary sepsis compared to pulmonary sepsis and associates with risk of ARDS and other organ dysfunction. Ann Intensiv Care. 2017;7:102.
Hutchings SD, Watchorn J, Trovato F, Napoli S, Mujib SF, Hopkins P, McPhail M. Microcirculatory, endothelial and inflammatory responses in critically ill patients with COVID-19 are distinct from those seen in septic shock: a case control study. Shock. 2020. https://doi.org/10.1097/SHK.0000000000001672.
Oda K, Okada H, Suzuki A, Tomita H, Kobayashi R, Sumi K, Suzuki K, Takada C, Ishihara T, Suzuki K, Kano S, Kondo K, Iwashita Y, Yano H, Zaikokuji R, Sampei S, Fukuta T, Kitagawa Y, Okamoto H, Watanabe T, Kawaguchi T, Kojima T, Deguchi F, Miyazaki N, Yamada N, Doi T, Yoshida T, Ushikoshi H, Yoshida S, Takemura G, Ogura S. Factors enhancing serum Syndecan-1 concentrations: a large-scale comprehensive medical examination. J Clin Med. 2009;8(9):1320.
Smart L, Bosio E, Macdonald SPJ, Dull R, Fatovich DM, Neil C, Arendts G. Glycocalyx biomarker syndecan-1 is a stronger predictor of respiratory failure in patients with sepsis due to pneumonia, compared to endocan. J Crit Care. 2018;47:93–8.
Fraser DD, Cepinskas G, Slessarev M, Martin C, Daley M, Miller MR, O'Gorman DB, Gill SE, Patterson EK, Dos Santos CC. Inflammation profiling of critically ill coronavirus disease 2019 patients. Crit Care Explor. 2020;2(6):e0144.
Omoto Y, Yamanaka K, Tokime K, et al. Granzyme B is a novel interleukin-18 converting enzyme. J Dermatol Sci. 2010;59:129–35.
Suzuki K, Okada H, Takemura G, Takada C, Kuroda A, Yano H, Zaikokuji R, Morishita K, Tomita H, Oda K, Matsuo S, Uchida A, Fukuta T, Sampei S, Miyazaki N, Kawaguchi T, Watanabe T, Yoshida T, Ushikoshi H, Yoshida S, Maekawa Y, Ogura S. Neutrophil Elastase damages the pulmonary endothelial Glycocalyx in lipopolysaccharide-induced experimental Endotoxemia. Am J Pathol. 2019;189(8):1526–35.
Doi K, Ikeda M, Hayase N, Moriya K, Morimura N. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care. 2020;24(1):392.
Jang S, Rhee JY. Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. Int J Infect Dis. 2020;96:500–2.
Hardy M, Lecompte T, Douxfils J, Lessire S, Dogné JM, Chatelain B, Testa S, Gouin-Thibault I, Gruel Y, Medcalf RL, Ten Cate H, Lippi G, Mullier F. Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory. Thromb J. 2020;18:17.
Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, Rangarajan ES, Pan A, Vanderheiden A, Suthar MS, Li W, Izard T, Rader C, Farzan M, Choe H. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11(1):6013.